Syndax Pharmaceuticals Inc. (NASDAQ:SNDX)’s share price hit a new 52-week high during trading on Tuesday . The company traded as high as $18.03 and last traded at $17.09, with a volume of 245,976 shares changing hands. The stock had previously closed at $14.94.

SNDX has been the subject of a number of research analyst reports. Zacks Investment Research upgraded Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, June 16th. Oppenheimer Holdings Inc. reaffirmed a “buy” rating and issued a $24.00 price target on shares of Syndax Pharmaceuticals in a research report on Tuesday, May 17th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Syndax Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $25.00.

The company’s market cap is $307.93 million. The stock’s 50 day moving average price is $12.46 and its 200-day moving average price is $13.11.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings results on Tuesday, August 9th. The company reported ($0.47) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.54) by $0.07. On average, equities research analysts expect that Syndax Pharmaceuticals Inc. will post ($3.01) earnings per share for the current fiscal year.

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications. Syndax is developing entinostat with a focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma, ovarian cancer and triple-negative breast cancer (TNBC).